Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Aderbasib (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2019 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.